Skip to content
Sign in
Artwork for U.S. Supreme Court Oral Arguments
U.S. Supreme Court Oral Arguments · April 29 · 1 hr

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

A case in which the Court held that a generic drug manufacturer does not actively induce patent infringement under 35 U.S.C. §271(b) when its communications consist only of legally required labeling, standard industry language, omissions, and vague statements that lack any affirmative purpose of encouraging the patented use.

0:00-1:00:20
Play in podnod

transcript

No transcript — this publisher did not publish one.

show notes

A case in which the Court held that a generic drug manufacturer does not actively induce patent infringement under 35 U.S.C. §271(b) when its communications consist only of legally required labeling, standard industry language, omissions, and vague statements that lack any affirmative purpose of encouraging the patented use.

more episodes

All episodes